Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

David B. Page, Harry Bear, Sangeetha Prabhakaran, Margaret E. Gatti-Mays, Alexandra Thomas, Erin Cobain, Heather McArthur, Justin M. Balko, Sofia R. Gameiro, Rita Nanda, James L. Gulley, Kevin Kalinsky, Julia White, Jennifer Litton, Steven J. Chmura, Mei Yin Polley, Benjamin Vincent, David W. Cescon, Mary L. Disis, Joseph A. SparanoElizabeth A. Mittendorf, Sylvia Adams

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.

Original languageEnglish (US)
Article number34
Journalnpj Breast Cancer
Volume5
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Blocking Antibodies
Breast Neoplasms
Radiotherapy
Ligands
Drug Therapy
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Page, D. B., Bear, H., Prabhakaran, S., Gatti-Mays, M. E., Thomas, A., Cobain, E., ... Adams, S. (2019). Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. npj Breast Cancer, 5(1), [34]. https://doi.org/10.1038/s41523-019-0130-x

Two may be better than one : PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. / Page, David B.; Bear, Harry; Prabhakaran, Sangeetha; Gatti-Mays, Margaret E.; Thomas, Alexandra; Cobain, Erin; McArthur, Heather; Balko, Justin M.; Gameiro, Sofia R.; Nanda, Rita; Gulley, James L.; Kalinsky, Kevin; White, Julia; Litton, Jennifer; Chmura, Steven J.; Polley, Mei Yin; Vincent, Benjamin; Cescon, David W.; Disis, Mary L.; Sparano, Joseph A.; Mittendorf, Elizabeth A.; Adams, Sylvia.

In: npj Breast Cancer, Vol. 5, No. 1, 34, 01.12.2019.

Research output: Contribution to journalReview article

Page, DB, Bear, H, Prabhakaran, S, Gatti-Mays, ME, Thomas, A, Cobain, E, McArthur, H, Balko, JM, Gameiro, SR, Nanda, R, Gulley, JL, Kalinsky, K, White, J, Litton, J, Chmura, SJ, Polley, MY, Vincent, B, Cescon, DW, Disis, ML, Sparano, JA, Mittendorf, EA & Adams, S 2019, 'Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer', npj Breast Cancer, vol. 5, no. 1, 34. https://doi.org/10.1038/s41523-019-0130-x
Page, David B. ; Bear, Harry ; Prabhakaran, Sangeetha ; Gatti-Mays, Margaret E. ; Thomas, Alexandra ; Cobain, Erin ; McArthur, Heather ; Balko, Justin M. ; Gameiro, Sofia R. ; Nanda, Rita ; Gulley, James L. ; Kalinsky, Kevin ; White, Julia ; Litton, Jennifer ; Chmura, Steven J. ; Polley, Mei Yin ; Vincent, Benjamin ; Cescon, David W. ; Disis, Mary L. ; Sparano, Joseph A. ; Mittendorf, Elizabeth A. ; Adams, Sylvia. / Two may be better than one : PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. In: npj Breast Cancer. 2019 ; Vol. 5, No. 1.
@article{cd7d65a239044beba3612d3640da9cf0,
title = "Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer",
abstract = "Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.",
author = "Page, {David B.} and Harry Bear and Sangeetha Prabhakaran and Gatti-Mays, {Margaret E.} and Alexandra Thomas and Erin Cobain and Heather McArthur and Balko, {Justin M.} and Gameiro, {Sofia R.} and Rita Nanda and Gulley, {James L.} and Kevin Kalinsky and Julia White and Jennifer Litton and Chmura, {Steven J.} and Polley, {Mei Yin} and Benjamin Vincent and Cescon, {David W.} and Disis, {Mary L.} and Sparano, {Joseph A.} and Mittendorf, {Elizabeth A.} and Sylvia Adams",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41523-019-0130-x",
language = "English (US)",
volume = "5",
journal = "npj Breast Cancer",
issn = "2374-4677",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Two may be better than one

T2 - PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

AU - Page, David B.

AU - Bear, Harry

AU - Prabhakaran, Sangeetha

AU - Gatti-Mays, Margaret E.

AU - Thomas, Alexandra

AU - Cobain, Erin

AU - McArthur, Heather

AU - Balko, Justin M.

AU - Gameiro, Sofia R.

AU - Nanda, Rita

AU - Gulley, James L.

AU - Kalinsky, Kevin

AU - White, Julia

AU - Litton, Jennifer

AU - Chmura, Steven J.

AU - Polley, Mei Yin

AU - Vincent, Benjamin

AU - Cescon, David W.

AU - Disis, Mary L.

AU - Sparano, Joseph A.

AU - Mittendorf, Elizabeth A.

AU - Adams, Sylvia

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.

AB - Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.

UR - http://www.scopus.com/inward/record.url?scp=85073571292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073571292&partnerID=8YFLogxK

U2 - 10.1038/s41523-019-0130-x

DO - 10.1038/s41523-019-0130-x

M3 - Review article

AN - SCOPUS:85073571292

VL - 5

JO - npj Breast Cancer

JF - npj Breast Cancer

SN - 2374-4677

IS - 1

M1 - 34

ER -